

## UNITED STATES DEPARTMENT OF COMMERCE Patent and Trademark Office

ASSISTANT SECRETARY AND COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

## APR 9 1991

Ronald L. Wilson, Director Health Assessment Policy Staff Office of Health Affairs (HFY-20) Food and Drug Administration 5600 Fishers Lane, Room 11-44 Rockville, MD 20857

RE: Dekantel Microflex Ophthalmic Suture FDA Docket NO. 91E-0091

Dear Mr. Wilson:

Transmitted herewith is a copy of the application for Patent Term Extension of U.S. Patent No. 4,621,638 issued November 11, 1986. The application was filed on February 22, 1991, under Title II of Public Law 98-417, the Drug Price Competition and Patent Term Restoration Act of 1984.

The patent claims a product that was subject to regulatory review under the Federal Food, Drug and Cosmetic Act. Subject to final review, the subject patent is considered to be eligible for patent term restoration. Thus, a determination of the applicable regulatory review period is necessary. Accordingly, notice and a copy of the application are provided pursuant to 35 USC § 156(d)(2)(A).

## C. E. Van Horn

Charles E. Van Horn Patent Policy and Programs Administrator Office of the Assistant Commissioner for Patents

cc: John L. LaPierre
Pfizer Inc.
Patent Department, 20th Floor
235 East 42nd Street
New York, N.Y. 10017-5755